2 rows where is-referenced-by-count = 13 sorted by funder_names

View and edit SQL

Suggested facets: created (date), subject (array), ISSN (array), orcids (array), names (array), award_numbers (array), funder_dois (array)

is-referenced-by-count

funder_names (array)

  • - 2
Link rowid title DOI URL created subject references-count is-referenced-by-count ISSN container-title abstract author_number orcids names award_numbers funder_names ▼ funder_dois
7 ["Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management"] 10.1136/gutjnl-2019-318404 http://dx.doi.org/10.1136/gutjnl-2019-318404 2019-08-19T15:35:18Z ["Gastroenterology"] 95 13 ["0017-5749", "1468-3288"] Gut <jats:p>Lactose is the main source of calories in milk, an essential nutriedigestion, patients with visceral hypersensitivity nt in infancy and a key part of the diet in populations that maintain the ability to digest this disaccharide in adulthood. Lactase deficiency (LD) is the failure to express the enzyme that hydrolyses lactose into galactose and glucose in the small intestine. The genetic mechanism of lactase persistence in adult Caucasians is mediated by a single C→T nucleotide polymorphism at the LCTbo −13’910 locus on chromosome-2. Lactose malabsorption (LM) refers to any cause of failure to digest and/or absorb lactose in the small intestine. This includes primary genetic and also secondary LD due to infection or other conditions that affect the mucosal integrity of the small bowel. Lactose intolerance (LI) is defined as the onset of abdominal symptoms such as abdominal pain, bloating and diarrhoea after lactose ingestion by an individual with LM. The likelihood of LI depends on the lactose dose, lactase expression and the intestinal microbiome. Independent of lactose digestion, patients with visceral hypersensitivity associated with anxiety or the Irritable Bowel Syndrome (IBS) are at increased risk of the condition. Diagnostic investigations available to diagnose LM and LI include genetic, endoscopic and physiological tests. The association between self-reported LI, objective findings and clinical outcome of dietary intervention is variable. Treatment of LI can include low-lactose diet, lactase supplementation and, potentially, colonic adaptation by prebiotics. The clinical outcome of these treatments is modest, because lactose is just one of a number of poorly absorbed carbohydrates which can cause symptoms by similar mechanisms.</jats:p> 4 ["http://orcid.org/0000-0002-8719-5175", "http://orcid.org/0000-0003-4394-5584"] ["Benjamin Misselwitz", "Matthias Butter", "Kristin Verbeke", "Mark R Fox"] [""] [""] [""]
8 ["Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer"] 10.1097/igc.0b013e31828566f1 http://dx.doi.org/10.1097/igc.0b013e31828566f1 2013-02-02T09:45:07Z [] 37 13 ["1048-891X", "1525-1438"] International Journal of Gynecologic Cancer <jats:sec><jats:title>Objectives</jats:title><jats:p>We sought to assess the response rate and toxicity of paclitaxel, carboplatin, andvorinostat primary induction therapy for the treatment of advanced-stage ovarian carcinoma.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients were treated with 6 cycles of weekly paclitaxel (80 mg/m<jats:sup>2</jats:sup>), carboplatin (6 times area under the curve), and vorinostat (200 mg) every 28 days according to an institutional review board–approved protocol. The subjects were eligible for response evaluation; in patients who achieved stable disease or better following the conclusion of primary induction chemotherapy, they were subsequently treated with a planned 12 cycles of paclitaxel (135 mg/m<jats:sup>2</jats:sup>) and vorinostat (400 mg) maintenance chemotherapy every 28 days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Eighteen patients received a combined 90 cycles (median, 6 cycles; range, 1–6 cycles) of primary induction chemotherapy. Of the 18 subjects, 7 demonstrated a complete response, and 2 subjects exhibited a partial response (a total response rate of 50.0%). Eight patients also received a combined total of 50 cycles (median, 5 cycles; range, 1–12 cycles) of consolidation therapy. Grade 3/4 neutropenia and thrombocytopenia were observed in 9 (56.3%) and 2 (12.5%) patients. One patient (6.3%) developed grade 3 anemia, and another (6.3%) manifested a grade 3 neuropathy. Remarkably, we observed a significant gastrointestinal event (eg, bowel anastomotic perforation) in 3 patients, which effectuated the study’s closure.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Because the current study was prematurely terminated, we cannot derive a conclusive assessment regarding the efficacy of this treatment. Nevertheless, the high incidence of severe gastrointestinal toxicity warrants further consideration when using vorinostat in the adjuvant setting for patients who have undergone a bowel res… 7 [] ["Alberto A. Mendivil", "John P. Micha", "John V. Brown", "Mark A. Rettenmaier", "Lisa N. Abaid", "Katrina L. Lopez", "Bram H. Goldstein"] [""] [""] [""]

Advanced export

JSON shape: default, array, newline-delimited

CSV options:

CREATE TABLE [article] (
   [title] TEXT,
   [DOI] TEXT,
   [URL] TEXT,
   [created] TEXT,
   [subject] TEXT,
   [references-count] TEXT,
   [is-referenced-by-count] TEXT,
   [ISSN] TEXT,
   [container-title] TEXT,
   [abstract] TEXT,
   [author_number] TEXT,
   [orcids] TEXT,
   [names] TEXT,
   [award_numbers] TEXT,
   [funder_names] TEXT,
   [funder_dois] TEXT
);